etoposide has been researched along with veliparib in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Beumer, J; Chen, A; Chen, Z; Christner, SM; Deng, X; Doho, GH; Khuri, FR; Kim, S; Kowalski, J; Li, C; Owonikoko, TK; Ramalingam, SS; Rossi, MR; Sica, GL; Strychor, S; Sun, SY; Switchenko, JM; Yue, P; Zhang, G | 1 |
| Aggarwal, C; Belani, CP; Dahlberg, SE; Dowell, J; Gerber, DE; Hann, CL; Khan, SA; Moss, RA; Owonikoko, TK; Ramalingam, SS | 1 |
| de Stanchina, E; Desmeules, P; Gardner, EE; Lok, BH; Ni, A; Poirier, JT; Powell, SN; Rekhtman, N; Riaz, N; Rudin, CM; Schneeberger, VE; Teicher, BA | 1 |
| Baker, K; Blackhall, F; Dive, C; Forster, M; Foy, V; Frese, KK; Gomes, F; Lallo, A; Schenk, MW | 1 |
| Atrafi, F; Byers, LA; Calles, A; Camidge, DR; Chae, YK; Gabrail, NY; Garralda, E; Groen, HJM; He, L; Hoening, E; Hu, B; Komarnitsky, P; Lolkema, MP; Nuthalapati, S; Sangha, RS; Tian, T; Viteri, S | 1 |
| Aggarwal, C; Cella, D; Dahlberg, SE; Feliciano, JL; Lash, BW; Leach, JW; Leal, TA; Mohindra, NA; Owonikoko, TK; Ramalingam, SS; Srkalovic, G; Steffen McLouth, LE; Wade, JL; Wagner, LI; Zhao, F | 1 |
| Bach, BA; Bentsion, D; Byers, LA; de Groot, P; Dunbar, M; Ellis, PM; Fujimoto, J; Gans, S; Gay, CM; Glasgow, J; Groen, HJM; He, L; Kang, K; Owonikoko, TK; Penkov, K; Sehgal, V; Sibille, A; Son, C | 1 |
1 review(s) available for etoposide and veliparib
| Article | Year |
|---|---|
Targeting DNA damage in SCLC.
Topics: Aurora Kinases; Azepines; Benzimidazoles; Carbolines; Cell Cycle Checkpoints; Cell Proliferation; Cytotoxins; DNA Damage; DNA Repair; Etoposide; Genomic Instability; Heterocyclic Compounds, 4 or More Rings; Humans; Lung Neoplasms; Molecular Targeted Therapy; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Rad51 Recombinase; Small Cell Lung Carcinoma | 2017 |
4 trial(s) available for etoposide and veliparib
| Article | Year |
|---|---|
A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Etoposide; Fatigue; Female; Heart Failure; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Thrombocytopenia | 2015 |
A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Small Cell Lung Carcinoma; Treatment Outcome | 2019 |
Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Small Cell Lung Carcinoma | 2020 |
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Treatment Outcome | 2021 |
2 other study(ies) available for etoposide and veliparib
| Article | Year |
|---|---|
Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Cell Line, Tumor; Chemoradiotherapy; Cisplatin; Drug Synergism; Etoposide; Humans; In Vitro Techniques; Lung Neoplasms; Mice; Mice, Nude; Poly(ADP-ribose) Polymerase Inhibitors; Random Allocation; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2014 |
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Synergism; Etoposide; Gene Expression Regulation, Neoplastic; Genomics; Humans; Indoles; Mice; Nuclear Proteins; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Small Cell Lung Carcinoma; Temozolomide; Xenograft Model Antitumor Assays | 2017 |